NCT00354536View on ClinicalTrials.gov

In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

GSK716155 subcutaneous injections

albiglutide subcutaneous injection

BIOLOGICAL

placebo injection

placebo injection

Trial Locations (5)

32809

GSK Investigational Site, Orlando

33025

GSK Investigational Site, Miramar

78229

GSK Investigational Site, San Antonio

97239

GSK Investigational Site, Portland

96814-4224

GSK Investigational Site, Honolulu

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY